Effectiveness of Thiotriazolin in a Complex Treatment of the Patients with Acute Coronary Syndrome without ST Elevation

V.K. Taschuk, N.A. Solobiukova, A.A. Makarov


Background. According to ACC/AHA guidelines the short-term goal of the treatment of the patients with unstable angina is a relief of ischemia and prevention of ischemia associated events. Drugs with metabolic action used in a complex therapy along with the basic cardiotropic agents allow enhance the effectiveness of the treatment applied in whole. One of these medications is Thiotriazolin. The aim of the study is to prove more evident effectiveness of the treatment included Thiotriazolin (solution for injections, 25 mg/ml, for a course combined therapy) compared to the standard therapy of acute coronary syndrome (ACS) without ST elevation. Materials and methods. A hundred patients with ACT without ST elevation ended the clinical study (the basic group — 50 people, the control group — 50 people). The main performance indicator was a complex variable included assessment of the following parameters: increased ejection fraction by echo-cardiography over 5 %; reduced overall length of myocardial ischemia episodes within a day by daily ECG Holter monitoring data not less than 10 %; reduced number of ventricular fibrillations by daily ECG Holter monitoring not less than 10 %. Results. The average effectiveness in the basic group was 1.66 points, in the control one — 0.74 points (p < 0.001). The positive effect of the therapy by effectiveness scale was in 84 % and 54 % patients of the basic and control groups, respectively. The following statistically significant changes were revealed: overall length of myocardial ischemia episodes within a day (ECG by Holter) reduced by 26.91 and 11.71 % to the end of the study in the basic and control groups, respectively; daily number of ventricular fibrillations (ECG by Holter) reduced by 34.45 and 30.70 % in the basic and control groups, respectively; end-diastolic volume decreased by 5.44 % in the basic group and increased by 0.5 % in the control group; ejection fraction enhanced by 4.99 % in the basic group and decreased by 0.53 % in the control group; systolic output index increased by 11.40 % and 2.42 % in the basic and control groups, respectively. All adverse reactions and events were predicted and non-serious. Conclusion. Course usage of Thiotriazolin, solution for injection, 25 mg/ml, produced by PC Galychfarm, Ukraine, as an element of a standard therapy of ACS without ST elevation statistically significant raises the effectiveness of the treatment.


Гелис Л.Г. Основные аспекты патогенеза, диагностики и лечения острого коронарного синдрома без стойкого подъема сегмента ST на ЭКГ / Л.Г. Гелис // Медицинские новости. — 2003. — № 9. — С. 27-32

Бобров В.А. Клиническое испытание препарата Тиотриазолин у больных острым инфарктом миокарда / В.А. Бобров. И.К. Следзевская, Л.С. Мхитарян, А.Н. Пархоменко. — К.: Фарм. комитет МЗ Украины, 1993. — 15 с.

Лоллини В.А. Применение тиотриазолина у больных с острым инфарктом миокарда / В.А. Лоллини, Т.Ф. Лысенко, Л.Г. Андаралова [и др.] // Медицинские новости. — 2008. — № 11. — С. 65-66.

Нетяженко В.З. Роль препаратов метаболического действия в комплексном лечении больных острым инфарктом миокарда / В.З. Нетяженко, Т.Д. Залевская // режим доступа: http://www.mif-ua.com/archive/article/6390

Поливода С.Н. Отчет о клинических испытаниях препарата тиотриазолин у больных постинфарктной стенокардией / С.Н. Поливода. — Запорожье, 1993. — 122 с.

Оценка клинической эффективности и переносимости Тиотриазолина у больных с нестабильной стенокардией / Е.П. Свищенко, Л.В. Безродная, В.П. Шпак [и др.] // Укр. терапевт. — 2009. — № 1. — С. 19-24.

Применение тиотриазолина в лечении больных острым коронарным синдромом / В.М. Боборынкин, М.С. Абдылаев, З.А. Жумашева [и др.] // Медицина. — 2011. — № 6. — С. 7-13.

Al-Khatib S.M. Sustained Ventricular Arrhythmias Among Patients with Acute Coronary Syndromes with no ST-Segment Elevation Incidence, Predictors, and Outcomes / S.M. Al-Khatib, C.B. Granger, Y. Huang [et al.], K.L. Lee // Circulation. — 2002. — Vol. 106, № 3. — P. 309-312.

Amsterdam E.A., Wenger N.K., Brindis R.G., Casey D.E. Jr, Ganiats T.G., Holmes D.R. Jr, Jaffe A.S., Jneid H., Kelly R.F., Kontos M.C., Levine G.N., Liebson P.R., Mukherjee D., Peterson E.D., Sabatine M.S., Smalling R.W., Zieman S.J. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines // Circulation. — 2014. — 130. — e344-e426.

Hersi A. Shortterm and longterm mortality associated with ventricular arrhythmia in patients hospitalized with acute coronary syndrome: findings from the Gulf RACE registry-2 / A. Hersi, K.F. Alhabib, A.A. Alsheikh // Coron. Artery. Dis. — 2013. — Vol. 24 (2). — P. 1604.

Mancini G.B.J. Prognostic Importance of Coronary Anatomy and Left Ventricular Ejection Fraction Despite Optimal Therapy / G.B.J. Mancini, P.M. Hartigan // Am. Heart J. — 2013. — Vol. 166. — P. 481-487.

Nademanee K. Prognostic Significance of Silent Myocardial Ischemia in Patients With Unstable Angina / K. Nademanee, V. Intarachot, M.A. Josephson [et al.] // JACC. — 1987. — Vol. 10. — P. 1-9.

Reperfusion therapy for ST elevationacute myocardial infarction in Europe: description of the current situation in 30 countries / P. Widimsky, W. Wijns, J. Fajadet [et al.] // Eur. Heart J. — 2010. — Vol. 31. — P. 943-957.

Romeo F. Unstable Angina: Role of Silent Ischemia and Total Ischemic Time (Silent Plus Painful Ischemia), a 6-Year Follow-Up / F. Romeo, G.M.C. Rosano, E. Martuscelli, A. Valente, A. Reale // JACC. — 1992. — Vol. 19, № 6. — P. 1173-9.

Scott D. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients / Scott D. Solomon, MD; Nagesh Anavekar, MD; Hicham Skali John [et al.] // Circulation. — 2005. — Vol. 112. — P. 3738-3744.

WHO Fact sheet N8310, updated June 2011, режим доступа: http://www.who.int/mediacentre/factsheets/fs310/en/index.html

DOI: https://doi.org/10.22141/2224-0586.8.79.2016.90371


  • There are currently no refbacks.

Copyright (c) 2017 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта